EAU 2018: Molecular and Histopathological Heterogeneity in Muscle-Invasive Bladder Cancer
Copenhagen, Denmark (UroToday.com) Dr. Antonio Lopez-Beltran from Spain gave a talk on molecular and histopathological heterogeneity in muscle invasive bladder cancer (MIBC). Dr. Lopez-Beltran started by highlighting that urothelial carcinoma has two morphologic and molecular phenotypes: non-muscle invasive bladder cancer (NMIBC; 70-80%) and MIBC (20-30%).
EAU 2018: The Critically Ill Patient with Locally Advanced Bladder Cancer – Ureterocutaneostomy? YES
Copenhagen, Denmark (UroToday.com) Dr. Armin Pycha from Bolzano, Italy provided the “yes” argument for ureterocutaneostomy in critically ill patients with locally advanced bladder cancer.
EAU 2018: The Critically Ill Patient with Locally Advanced Bladder Cancer – Ureterocutaneostomy? NO
Copenhagen, Denmark (UroToday.com) Dr. Siemer from Germany provided the rebuttal to Dr. Pycha’s “yes” for ureterocutaneostomy in the critically ill patients with locally advanced bladder cancer. As Dr. Siemer notes, when treating the critically ill patient there is a balance between survival and quality of life/potential complications.
EAU 2018: Optimizing Anesthesia in the Frail Patient with Bladder Cancer: What the Urologist Needs to Know
Copenhagen, Denmark (UroToday.com) Dr. Wuethrich from Switzerland succinctly summarized anesthesia concerns for frail, elderly patients with bladder cancer. Dr. Wuethrich commenced by noting that frailty is the outcome of two combined effects: the aging process and superimposed injuries (chronic disease, psychological and social stress). From a geriatrician perspective, patients with frailty should be treated if they are (i) depressed, (ii) require testosterone replacement therapy, (iii) have hypothyroidism, and (iv) require vascular disease treatment. Exercise is a cornerstone of the management of frailty at least three times per week, and elderly people who are eating poorly should be encouraged to increase their food intact including vitamins.
EAU 2018: Urothelial Cancer – A Year in Highlights
Copenhagen, Denmark (UroToday.com) Dr. Powles gave an overview of the recent highlights and advances in the treatment of urothelial cancer. Immune checkpoint inhibitors (ICI) are the biggest advancement in urothelial cancer and the licensed ICI in metastatic urothelial cancer (MUC) are shown in figure 1.
EAU 2018: Clinicopathologic Factors Linked to Intravesical Recurrence after Radical Nephroureterectomy to Treat Upper Tract Urothelial Carcinoma
Copenhagen, Denmark (UroToday.com) Dr. Seisen proided a talk which focused on the clinicopathology factors linked to intravesical recurrence (IVR) following radical nephroureterectomy (RNU) to treat upper tract urothelial carcinoma. His talk was primarily based on the recent systematic review that he spearheaded (Seisen et al, European Urology, 2014). This has since been translated into the guidelines for the EAU.
EAU 2018: Can We Rely on Urinary Markers?
Copenhagen, Denmark (UroToday.com) Dr. Shariat was tasked with addressing the role of urinary markers for UTUC. He provided a summary of the current landscape in his presentation.